September 2014
RP101 has been granted Orphan Drug designation for the adjunct treatment of pancreatic cancer by FDA and EMA ...
by Lloyd Dunlap

September 2014
Oral treatment for spinal muscular atrophy appears effective in mice ...
by Zack Anchors

September 2014
Scripps Research Institute scientists find that cancer drug rapamycin may help bypass blood stem cell defenses...
by Lori Lesko

August 2014
A decade on, nanomedicines may finally be ready to jump to the fore...
by Randall C Willis

August 2014
Irish biopharmaceutical giant agrees to $54.8-billion deal...
by Kelsey Kaustinen

August 2014
Natural substance could be real cure for AIDS, says Hemispherx...
by Ilene Schneider


ASHG 2014 Preview:
Shining a light on human genetics in sunny San Diego
Reportedly the largest human genetics meeting and exposition in the world, the 64th Annual Meeting of the American Society of Human Genetics (ASHG) from Oct. 18 to 22 will cover ethics in genomics, advances in sequencing and much else, attracting more than 6,500 scientific attendees and featuring well over 200 exhibiting companies. Find out more about the show, whether to get ready for your own attendance or to determine whether you should go. Read more

And from ISSCR 2014, here are  reports from the field by DDNews Features Editor Randall C Willis ...
"Taking stem cells from bench to business"
"Building a better model"
"Shifting stem cell regulatory landscape"
"Patients' growing impatience for cell therapies"

 Our 2015 Media Kit is now available

Your gateway to the latest oncology news, trends and resources

September 2014
The U.S. Food and Drug Administration was been busy in spring 2014, releasing two new guidances (in May and August) relating to its evolving standards for satisfying the biosimilarity requirements of the Biologics Price Competition and Innovation Act... [ more ]
by Kevin Noonan

September 2014
Off-label prescribing of pharmaceutical products by physicians has a long history and even some notable successes, but the practice also poses many challenges and risks... [ more ]
by Randall C Willis

September 2014
There is no doubt that Ebola is a monumental problem, and it's a notable part of our September issue coverage. But there's also been a lot of excessive fear and hype as well, which has perhaps made the disease look like something out of an apocalyptic novel or film. On the bright side, the increased attention seems to have mobilized many pharmas, biotechs, government agencies and others to increase the pace of Ebola diagnostics and therapies, which could be welcome relief to the people most at risk of the disease... [ more ]
by Jeffrey Bouley